The Percentage of PD-L1 Besides 50% Positivity Predicts Objective Response to Pembrolizumab in Non-Small Cell Lung Cancer

被引：0
|
作者：
Poma, A. [1 ]
Pasquini, G. [2 ]
Bruno, R. [3 ]
Ali, G. [3 ]
Proietti, A. [3 ]
Pecora, I. [2 ]
Petrini, L. [2 ]
Vasile, E. [2 ]
Chella, A. [4 ]
Fontanini, G. [1 ]
机构：
[1] Univ Pisa, Dept Surg Med Mol Pathol & Crit Area, Pisa, Italy
[2] Azienda Osped Univ Pisana, Med Oncol, Pisa, Italy
[3] Univ Hosp Pisa, Anat Pathol Unit, Pisa, Italy
[4] Azienda Osped Univ Pisana, Pneumo Oncol, Pisa, Italy
来源：
JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期
关键词：
lung cancer; PD-L1; immunotherapy;
D O I：
10.1016/j.jtho.2019.08.969
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.04-66
引用
收藏
页码：S466 / S467
页数：2
相关论文
共 50 条
  • [21] PD-L1 expression: An emerging biomarker in non-small cell lung cancer
    Adam, Julien
    Planchard, David
    Marabelle, Aurelien
    Soria, Jean-Charles
    Scoazec, Jean-Yves
    Lantuejoul, Sylvie
    ANNALES DE PATHOLOGIE, 2016, 36 (01) : 94 - 102
  • [22] PD-L1 expression is associated with advanced non-small cell lung cancer
    Chen, Zhiquan
    Mei, Jiandong
    Liu, Lunxu
    Wang, Guochen
    Li, Zuosheng
    Hou, Jingpu
    Zhang, Qiuyang
    You, Zongbing
    Zhang, Liu
    ONCOLOGY LETTERS, 2016, 12 (02) : 921 - 927
  • [23] Mitomycin C synergizes with PD-L1 blockade in treatment of non-small cell lung cancer
    LUO Min
    ZHANG Hong
    WU Shao-cong
    CHEN Zhen
    LIANG Shao-bo
    WANG Fang
    FU Li-wu
    中国药理学与毒理学杂志, 2019, (10) : 885 - 885
  • [24] Biomarkers of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Beyond PD-L1
    Cabezon-Gutierrez, Luis
    Custodio-Cabello, Sara
    Palka-Kotlowska, Magda
    Alonso-Viteri, Soledad
    Khosravi-Shahi, Parham
    CLINICAL LUNG CANCER, 2021, 22 (05) : 381 - 389
  • [25] PD-L1 Expression by RNA-Sequencing in Non-Small Cell Lung Cancer: Concordance with Immunohistochemistry and Associations with Pembrolizumab Treatment Outcomes
    Nesline, Mary K.
    Previs, Rebecca A.
    Dy, Grace K.
    Deng, Lei
    Lee, Yong Hee
    Depietro, Paul
    Zhang, Shengle
    Meyers, Nathan
    Severson, Eric
    Ramkissoon, Shakti
    Pabla, Sarabjot
    Conroy, Jeffrey M.
    CANCERS, 2023, 15 (19)
  • [26] Inter-tumor heterogeneity of PD-L1 expression in non-small cell lung cancer
    Saito, Yuichi
    Horiuchi, Sho
    Morooka, Hiroaki
    Ibi, Takayuki
    Takahashi, Nobumasa
    Ikeya, Tomohiko
    Shimizu, Yoshihiko
    Hoshi, Eishin
    JOURNAL OF THORACIC DISEASE, 2019, 11 (12) : 4982 - 4991
  • [27] Gene expression profile of high PD-L1 non-small cell lung cancers refractory to pembrolizumab
    Jamila Talb
    Paul Takam Kamga
    Marie Mayenga
    Adrien Costantini
    Catherine Julié
    Coraline Dumenil
    Jennifer Dumoulin
    Julia Ouaknine
    Violaine Giraud
    Cécile Dujon
    Reza Azarian
    Claire Glaser
    Jean-François Emile
    Etienne Giroux Leprieur
    Cancer Immunology, Immunotherapy, 2022, 71 : 2791 - 2799
  • [28] Inter-tumor Heterogeneity of PD-L1 Expression in Non-small Cell Lung Cancer
    Saito, Y.
    Wakimoto, S.
    Morooka, H.
    Ibi, T.
    Yamauchi, Y.
    Takahashi, N.
    Shimizu, Y.
    Ikeya, T.
    Sakao, Y.
    Kawamura, M.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S568 - S569
  • [29] PD-L1 on large extracellular vesicles is a predictive biomarker for therapy response in tissue PD-L1-low and -negative patients with non-small cell lung cancer
    Schoene, Nadja
    Kemper, Marcel
    Menck, Kerstin
    Evers, Georg
    Krekeler, Carolin
    Schulze, Arik Bernard
    Lenz, Georg
    Wardelmann, Eva
    Binder, Claudia
    Bleckmann, Annalen
    JOURNAL OF EXTRACELLULAR VESICLES, 2024, 13 (03)
  • [30] Resistance to PD-1/PD-L1 immune checkpoint blockade in advanced non-small cell lung cancer
    Li, Lijun
    Pu, Haihong
    Zhang, Xiaoxin
    Guo, Xiaotian
    Li, Guangrui
    Zhang, Minghui
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2025, 209
12345